Creative Medical Technology Holdings Inc (CELZ)

[uvaphd]

In case anyone has forgotten what AmnioStem is about (yes, THAT Amniostem—the one for which commercialization partnerships are now being planned, as we learned in the August 2019 update) and what it portends for the future PPS of CELZ:

https://www.marketwatch.com/press-release/creative-medical-technology-holdings-announces-superior-immune-modulatory-of-amniostem-stem-cells-compared-to-other-stem-cell-types-2018-04-04

PHOENIX, April 4, 2018 /PRNewswire/ -- Creative Medical Technology Holdings (otcqb:CELZ) announced today new data demonstrating superior immune modulatory ability of its AmnioStem™ stem cell product when compared head-to-head with bone marrow, adipose tissue, and placental tissue mesenchymal stem cells. The data, which was generated by the Company at its BioLabs research facility in San Diego, showed that AmnioStem™ cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells.

"Control of molecules such as TNF-alpha represents a multi-billion dollar market. Currently drugs like Humira, Remicade, and Embrel, which are antibodies blocking the TNF-alpha pathway, have sales of over $30 billion per year," said Thomas Ichim, Ph.D, Cofounder and Chief Scientific Officer of Creative Medical Technology Holdings. "Using cells as drugs represents a more viable alternative to existing approaches because the stem cells not only reduce inflammation, but also has the ability to induce healing of injured tissue.

"We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market. In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem™ technology include Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, and Lupus," said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. "I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type."

The AmnioStem™ stem cell is covered by an issued US Patent that was exclusively licensed from the University of California by the Company in 2016.”